Aradigm Corp (NASDAQ:ARDM) CEO Interview

This interview has expired.
Click here to find stocks, with exciting stories, and management committed to maximizing shareholder value.

Special deals for our readers
Are you qualified for the Visa Black Card?
The World’s Most Prestigious and Versatile Credit Card. Apply Now!

Be a more profitable investor:
What’s Jim Cramer trading in his personal portfolio? Click here

Get an Equifax 3-in-1 Credit Report Now!

Why are you still paying too much with Schwab, and and E-trade?? Step up to the #1 discount broker: TradeKing.
Find out why TradeKing.com was ranked #1 Discount Broker by SmartMoney Magazine two years running! (August 2006 & 2007).

Invest Smarter! Get 4 Bonus Weeks of Investor’s Business Daily Digital Edition!

LifeLock is the only Identity Theft Prevention Solution backed by a one-million dollar guarantee!Click here to get a 10% discount.

Get FICO Score Watch Now!

Free Quicken Online automatically categorizes your expenses.

Click here to get access to powerful investing tools only available at Investor’s Business Daily.

Get a free look at Jim Cramer’s Action Alerts PLUS portfolio. Click here

Aradigm Corp
(NASDAQ:ARDM)
Dr. Igor Gonda, CEO

Aradigm Corporation is a specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Product candidates in development include both the Company’s own products and products under development with collaborators. They consist of approved drugs combined with the Company’s inhalation delivery and/or formulation technologies. The Company’s programs under development include ARD-3100 (Liposomal ciprofloxacin), ARD-3150 (Liposomal ciprofloxacin), ARD-1100 (Liposomal ciprofloxacin) and ARD-1600 (Nicotine). Its collaborative programs under development include ARD-1550 (Inhaled treprostinil), ARD-1500 (Inhaled liposomal treprostinil) and ARD-1700 (combination products).




Be the first to comment

Leave a Reply